Omeros Corporation
OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has compleā¦ read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$11.84
Price-0.76%
-$0.09
1Y
Price
Market Cap
$856.924m
Small
Price/Earnings 3y Avg5y Avg
5.4x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$9.893m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
$86.170m
+22.7%
1y CAGR-119.6%
3y CAGR-54.1%
5y CAGREPS
$1.30
+25.2%
1y CAGR-175.7%
3y CAGR-153.1%
5y CAGRBook Value
-$63.334m
$286.173m
Assets$349.507m
Liabilities$310.632m
DebtDebt to Assets
108.6%
-1.7x
Debt to EBITDAFree Cash Flow
-$94.783m
+29.3%
1y CAGR-28.5%
3y CAGR-16.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company